Kornimate/medical-research-clean huggingface dataset:
boron neutron capture therapy in treating patients with glioblastoma multiforme or melanoma metastatic to the brain

Conditions: Brain and Central Nervous System Tumors; Melanoma (Skin); Metastatic Cancer

Summary: rationale: radiation therapy such as boron neutron capture therapy may kill tumor cells without harming normal tissue. purpose: phase i/ii trial to study the effectiveness of boron neutron capture therapy in treating patients who have glioblastoma multiforme or melanoma metastatic to the brain.

objectives: * determine the time course, uniformity, and severity of acute and chronic normal tissue reactions in patients with glioblastoma multiforme or intracranial melanoma treated with boronophenylalanine-fructose complex (bpa-f) followed by cranial neutron irradiation using a new fission converter beam facility. * determine the maximum tolerated dose of cranial neutron capture therapy in these patients. * determine, through serial objective measurements, the clinical response in patients treated with this therapy. * determine the pharmacokinetics of bpa-f in these patients. outline: this is a dose-escalation study of cranial neutron capture therapy (nct). patients receive boronophenylalanine-fructose complex iv over 90 minutes followed by cranial nct on days 1 and 2. cohorts of 3-6 patients receive escalating doses of nct until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. once the mtd is determined, additional patients are treated at the mtd. patients are followed at 1, 2, 4, 6, 9, and 12 months and then every 6 months for 2 years. projected accrual: a total of 16 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * histologically confirmed glioblastoma multiforme or * radiographically diagnosed brain metastases after a diagnosis of melanoma * contrast-enhanced tumor volume must not exceed 60 ml patient characteristics: age: * 18 and over performance status: * ecog 0-2 life expectancy: * at least 6 months hematopoietic: * not specified hepatic: * not specified renal: * creatinine normal cardiovascular: * no prior severe cardiac disease, including the following: * uncontrolled arrhythmias or conduction defects * unstable or newly diagnosed angina pectoris * recent coronary artery disease * congestive heart failure other: * not pregnant * negative pregnancy test * fertile patients must use effective contraception during and for at least 6 months after study * no prior phenylketonuria * no cognitive impairment that would preclude informed consent prior concurrent therapy: biologic therapy: * not specified chemotherapy: * no concurrent chemotherapy endocrine therapy: * not specified radiotherapy: * no prior cranial irradiation surgery: * not specified

Keywords: adult glioblastoma stage iv melanoma tumors metastatic to brain adult giant cell glioblastoma adult gliosarcoma
hyperhomocysteinemia in alzheimer's disease

Conditions: Alzheimer Disease; Homocystinemia

Summary: alzheimer's disease (ad) is the most common neurodegenerative disease. age is its main risk factor. ad is a multifactorial disease, combining genetic and environmental risk factors. autosomal dominant mutations have been identified (psen1, psen2, app), leading to earlier and more severe forms of the disease. other genetic risk factors have been identified, such as the ε4 allele of the apoe gene. . the environment also plays a major role, with the identification of several risk factors such as air pollution or nutritional deficiencies. ad patients frequently present hyperhomocysteinemia, a consequence of a dysfunction of monocarbon metabolism. homocysteine is an amino acid involved in the metabolism of methionine and cysteine. high concentrations of homocysteine can be deleterious to the central nervous system. most prospective studies have shown that elevated homocysteine is a predictor of undefined cognitive impairment or ad. other studies have focused on clinical data and, in particular, on cognitive function. for example, a meta-analysis found an inverse correlation between mmse score and homocysteine level. thus, our study seeks to evaluate the impact of hyperhomocysteinemia on the severity and early onset of ad, while knowing the presence or absence of genetic risk factors associated with ad.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of alzheimer's disease * positive csf biomarkers * age of onset \< 75 years * already benefited from a previous research of alzheimer's disease genetic features (psen1, psen2, app, apoe) * already benefited from a previous research of homocysteine cycle (monocarbon metabolism) by complete exome/clinical exome or panel exclusion criteria: * patient refusal
safety and pharmacokinetics of famciclovir single 1500 mg dose in adolescents with recurrent herpes labialis

Conditions: Herpes Labialis

Summary: this study will assess the safety, tolerability of a single 1500 mg dose of famciclovir in 50 adolescents with recurrent herpes labialis. eight of the 50 adolescents will also participate in the pharmacokinetics (pk) assessment of famciclovir single 1500 mg dose

uncontrolled study

Eligibility criteria:
inclusion criteria: * outpatient males or females 12 to \<18 years of age * general good health with a documented history typical for recurrent herpes labialis * prodromal symptoms or active lesions suggestive of a recurrent episode of herpes labialis (i.e. having had cold sores in the past) , with onset not exceeding 24 hours until the time of study drug administration * adolescents participating in pharmacokinetics (pk) part of the study may be enrolled without an active herpes labialis recurrence or with onset of signs/symptoms of a recurrent herpes labialis episode longer than 24 hours before study drug administration, all adolescents participating in the pharmacokinetics assessments must fast for at least 8 hours prior to visit 1 and be willing to fast for an additional 2 hours after study drug administration exclusion criteria: * use of other investigational drugs within 30 days of enrollment * history of hypersensitivity to famciclovir or penciclovir * inability to swallow tablets * body weight less than 40 killograms (kg) * history of malabsorption, unless a condition like celiac disease is stable and well controlled, previous gastrointestinal surgery or radiation therapy that could affect drug absorption or metabolism, or any condition that could interfere with drug absorption, distribution, metabolism, or excretion * known renal insufficiency (calculated creatinine clearance \<60 \[milliliters/minutes\] ml/min) * known severe hepatic impairment (child-pugh class c) * significant skin disease such as atopic dermatitis or eczema that would interfere with assessment of oral/labial lesions * known to be immunocompromised or are receiving systemic or using topical immunosuppressive agents (including corticosteroids, tacrolimus and picrolimus) within 30 days of enrollment * concomitant use of probenecid * pregnant or nursing (lactating) females * females of child-bearing potential, unless they are using two birth control methods. the two methods can be a double barrier method or a barrier method plus a hormonal method.

Keywords: herpes labialis cold sores herpes simplex type 1
effect of pursed-lip breathing on blood pressure and heart rate

Conditions: Hypertensive Urgency

Summary: hypertensive urgency (ht urgency) is an alarm sign of uncontrolled hypertension. it can be aggravated by nonadherent to medication and psychosocial stress. mindfulness is beneficial for reducing stress, while deep and slow breathing is effective for blood pressure (bp) lowering. the objective of the study was to assess the effect of pursed-lip breathing with number counting (plb with nc) that promotes mindfulness and a deep/slow breathing pattern on bp and heart rate (hr) in the ht urgency patients.

this was a single-blinded randomized controlled trial. patients aged between 18-80 years old, diagnosed with ht urgency, who presented at the emergency room of srinagarind hospital (a 1000-bed, tertiary-care level university hospital), khon kaen university between september 1st, 2019 to june 30th, 2020, were enrolled. those with cardiac arrhythmias, acute hf, acute coronary syndromes, acute stroke, acute respiratory failure, alteration of consciousness, and pregnant women were excluded. this study was approved by the khon kaen university ethical review board in human research (he611586). all patients gave their written informed consent before the enrollment.ht urgency was defined as sbp \>180 mmhg and/or dbp \>110 mmhg without any signs or symptoms of target organ damages.

Eligibility criteria:
inclusion criteria: * 18-80 years old patients who diagnosed with ht urgency, who presented at the emergency room exclusion criteria: * patients with cardiac arrhythmias, * acute heart failure * acute coronary syndromes * acute stroke * acute respiratory failure * alteration of consciousness * pregnant women

Keywords: hypertensive crisis uncontrolled hypertension mindfulness slow breathing emergency room
effect of meibomian gland related therapy on the morphology of meibomian gland

Conditions: Xerophthalmia

Summary: 200 participants at eye hospital of wenzhou medical university during september, 2020 to november, 2020 will be enrolled in this study. the meibomian gland related therapy are pulsed light therapy and meibomian gland hot compress massage.


Eligibility criteria:
inclusion criteria: * previously untreated patients with xerophthalmia exclusion criteria: * no history of ocular surgery and trauma * any eye diseases except xerophthalmia * no treated for xerophthalmia before * successful completion of follow-ups
combined effects of pnf and electrical muscle stimulation on spasticity and hand function in stroke patients.

Conditions: Stroke; Proprioceptive Disorders; Balance; Distorted

Summary: to determine the combined effects of proprioceptive neuromuscular facilitation and electrical muscle stimulation on spasticity and hand function in stroke patients.

it will be a randomized controlled trial. the stroke patients aged between 30-70 years will be included in this study. participants will be selected with non-probability convenience sampling technique. participants will be randomly allocated into two groups by lottery method i.e experimental group and control group. the experimental group will receive proprioceptive neuromuscular technique (contract relax-10 repetition) (5-min) and electrical muscle stimulation(10 min) as 15 min session 3 times a week for four weeks while the control group will receive only conventional therapy. the outcome measure will be calculated by modified barthel index, modified ashworth scale and wolf motor function test.

Eligibility criteria:
inclusion criteria: * both ischemic and haemorrhagic stroke patients * chronic stroke patients from 6 month to 2years * mini mental scale examination (mmse) more than 25 exclusion criteria: * transient ischemic attack * recurrent stroke * stroke patient with comorbidity and cardiac disease * myopathies

Keywords: stroke proprioceptive disorders balance; distorted
azithromycin level in tears and in conjunctiva in 36 healthy volunteers

Conditions: Eye Infections, Bacterial

Summary: to evaluate azithromycin ocular conjunctiva concentrations 7 and 14 days after treatment initiation. to assess ocular and systemic tolerance/safety and azithromycin tear concentrations on day 7

the aim of the present study was to compare azithromycin tear and conjunctival ocular concentrations after one instillation of t1225 1.5% eye drops, twice a day during one day versus one instillation of t1225 1.5% eye drops, twice a day during 3 days versus an oral single dose of 1g azithromycin.

Eligibility criteria:
inclusion criteria: * written informed consent; * healthy volunteers; * registered in the national register of healthy volunteers; * male or female aged from 18 to 45 years old; * able to understand the study instructions; * likely to comply with the study schedule and treatment; * normal subjective ocular symptoms, schirmer test \> 10 mm in 5 min and corrected visual acuity \>= 6/10 in both eyes exclusion criteria: * ocular trauma, infection or inflammation within the last 3 months; * blepharitis; * conjunctival hyperaemia (score \>= 2); * fluorescein-stained punctuations (score \>= 1b); * hypersensitivity to one of the products used in the study; * clinically relevant allergy; * medical or surgical history incompatible with the study; * recent acute illness; * ocular surgery, including lasik, lasek and prk within the last 12 months; * other ocular lasers or zithromax® or azadose® within the last 3 months; * systemic antibiotics and ocular medications within the last month; * contact lenses within the last week; * any medication on day 0 and during the study (except paracetamol and contraceptives).
a study of zanubrutinib in patients with itp

Conditions: Immune Thrombocytopenia; Bruton Tyrosine Kinase

Summary: this project was undertaken to evaluate the efficacy and safety of btk inhibitor zanubrutinib for the secondary treatment of adults with primary immune thrombocytopenia (itp).

the investigators are undertaking a prospective trial of 10 adults with itp in china. zanubrutinib is administered as 80 mg po. qd for 6 weeks. platelet count, bleeding and other symptoms were evaluated before and after treatment. adverse events are also recorded throughout the study.

Eligibility criteria:
inclusion criteria: * confirmed primary refractory itp * platelet counts \<30×10\^9/l or with bleeding symptoms * willing and able to sign written informed consent exclusion criteria: * secondary thrombocytopenia * received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 6 months before the screening visit * hiv infection or hepatitis b virus or hepatitis c virus infections * malignancy * severe medical condition (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia) * nursing or pregnant patients * patients who are deemed unsuitable for the study by the investigator
longitudinal mri assessment in patients with diffuse low-grade gliomas

Conditions: Low-grade Glioma

Summary: retrospective longitudinal follow-up in patients with diffuse low-grade glioma with multimodal mri assessment


Eligibility criteria:
inclusion criteria: * initial who grade ii * at least 3 exploitable mri each including a morphologic flair sequence and perfusion imaging exclusion criteria: -major protected person ( trusteeship, curatorship, justice safeguard)

Keywords: glioma magnetic resonance imaging magnetic resonance angiography disease progression supratentorial neoplasms blood volume contrast media gadolinium dtpa image processing, computer-assisted neovascularization, pathologic diffuse low grade glioma relative regional cerebral blood volume ( rrcbv) early prognosis of anaplasic transformation diffuse low grade glioma anaplasic transformation
repetitive assessement of precise-dapt score

Conditions: Cardiovascular Diseases; Interventional Cardiology

Summary: patients treated with percutaneous coronary intervention (pci) require dual antiplatelet therapy (dapt). preliminary assessment of the precise-dapt score is mandatory in order to assess the risk of bleeding while on dapt. the score takes into consideration age, creatinine clearance, haemoglobin, white blood- cell count and previous spontaneous bleeding. one should consider, however, that some of the variables included in the precise-dapt score might change with time. as a consequence, the precise-dapt score should not be considered a static score as it might vary after the initial computation. it remains unknown, however, if the use of the delta precise-score, which reflects the change in score between baseline and follow-up, might help to improve the management of pci patients in order to decrease the bleeding risk during follow-up.

the re-score trial is a multicenter study aimed at comparing usual care of patients treated with pci with a novel strategy of change of therapy during follow-up on the base of the delta precise-dapt score, as assessed every 3 months in pci patients receiving dapt. the primary end-point of the study is the occurrence of bleeding, as defined according to the criteria of the bleeding academic research consortium (barc). the second end-point is a composite of cardiac death, myocardial infarction, stroke, definite or probable stent thrombosis (st), or barc criteria type 2, 3 or 5 bleeding.

Eligibility criteria:
inclusion criteria: * consecutive patients undergoing percutaneous coronary intervention * indication to dual antiplatelet therapy for at least 3 months exclusion criteria: - contraindications to dual antiplatelet therapy lasting more than 3 months

Keywords: dual anti-platelet therapy bleeding
a study of effectiveness and safety of abciximab in patients with acute ischemic stroke (abestt-ii)

Conditions: Cerebrovascular Accident; Brain Ischemia; Acute Disease

Summary: the purpose of this study is to determine the effectiveness of abciximab in the treatment of acute ischemic stroke.

abciximab is a drug that prevents platelets from sticking together and forming a clot. there are limited studies using abciximab in the treatment of strokes. this phase iii, multicenter, randomized, double-blind, placebo-controlled, parallel group study is designed to assess the effectiveness and safety of abciximab for treatment of acute ischemic stroke, in helping dissolve clots in brain arteries so that blood and oxygen can flow better and there may be less brain damage. safety evaluations will be performed at specified intervals throughout the study and will consist of laboratory tests, vital signs (such as blood pressure), physical examinations and the occurrence and severity of adverse events as well as other study specific procedures. patients will receive either abciximab: 0.25 mg/kg bolus (to a maximum of 30 mg) followed by a 0.125 µg/kg/min infusion (to a maximum of 10 µg/min) for 12 hours or a bolus of placebo followed by infusion for 12 hours

Eligibility criteria:
inclusion criteria: * patients with diagnosis of acute ischemic stroke with onset within 5 hours and 30 minutes before randomization and planned treatment initiation within 6 hours of onset * after 600 patients are enrolled in previous criteria, the new criteria for enrollment will be, patients with diagnosis of acute ischemic stroke with onset within 4 hours and 30 minutes before randomization and planned treatment initiation within 5 hours of onset exclusion criteria: * patients who had participation in another study with an investigational drug or device within the last 30 days, prior participation in the present study, or planned participation in another trial * patients with symptoms suggestive of subarachnoid hemorrhage * female patients known to be pregnant, lactating, or having a positive or indeterminate pregnancy test * patients with neurological deficit that has led to stupor or coma * patients with minor stroke

Keywords: acute ischemic stroke abciximab reopro drug safety drug efficacy intracranial hemorrhage stroke
neuroscience-informed treatment to remotely target reward mechanisms in post-acute anorexia nervosa

Conditions: Anorexia Nervosa

Summary: the investigators will recruit individuals with broadly-defined an (n = 80) who are currently in or have recently participated in higher-level eating disorder treatment (e.g., residential, partial hospitalization/day treatment, intensive outpatient treatment). interested participants will sign consent, complete eligibility assessments, and will be randomized to receive positive affect treatment for anorexia nervosa (pat-an) or psychoeducation and behavioral therapy (pbt) through teletherapy shortly following discharge from higher level of care. participants can participate in most other forms of outpatient treatment while receiving the research intervention. participants will engage in 24 weeks of pat-an or pbt starting in the first 3 months post-discharge. at each session, the investigators will complete brief measures assessing treatment acceptability, affect, and eating disorder symptoms. participants will also complete an assessment battery of self-report, ema, and neurocognitive measures evaluating primary outcomes (bmi; eating disorder symptoms), secondary outcomes (depression, anxiety, and suicidality), and presumed treatment mechanisms at baseline, end of treatment (eot), and 3-month follow-up (fu). all assessments will be remotely delivered via hipaa-compliant platforms.


Eligibility criteria:
inclusion criteria: 1. age \> or = 18 years old 2. ability to read and speak in english 3. dsm-5 diagnosis of an or atypical an at admission to higher-level care 4. in higher-level care discharging to outpatient care or discharged to outpatient care within the past 3 months 5. current bmi \> or = 18.5 kg/m2 (or will be by time of discharge) 6. bmi increase of \> or = 0.5 kg/m2 while in higher-level care 7. ability to designate and sign a release of information for a primary physical or mental health provider for study duration 8. willingness to participate in weekly assessments (e.g., weight monitoring) and audio or video recording of study therapy sessions for study duration 9. access to a smartphone and/or computer permitting engagement in remote therapy and assessment. exclusion criteria: 1. medical instability for outpatient care; 2. pregnancy 3. lifetime dsm-5 primary psychotic or bipolar-i disorder 4. current dsm-5 substance use disorder 5. enrollment in outpatient therapy with highly overlapping content to pat-an
vitamin d of chinese children and adolescents

Conditions: Vitamin D Deficiency

Summary: the aim of this study was to assess the vitamin d status and analyze risk factors for vitamin d inadequacy of chinese children and adolescents aged 6-17y.

in this study, we analyzed the vitamin d status of chinese children and adolescents aged 6-17y, and related risk factors (such as gender, region strata, ambient uvb level at area of residence, season, and outdoor time, etc.). serum 25 hydroxyvitamin d \[25(oh)d\] was measured with a radioimmunoassay kit in 15 000 children and adolescent participants in chinese national nutrition and health survey (cnnhs) 2010-2012. age, gender, region type, ethnicity, outdoor time, vitamin d supplementation were recorded in unified design questionnaires. season was recorded by the date of blood taken; location was divided into north and south by china's qinling mountains and huaihe river; and ambient ultraviolet b (uvb) radiation level was classified according to the corresponding dose of each participant living area from national aeronautics and space administration data.

Eligibility criteria:
inclusion criteria: participanted in china national nutrition and health survey (cnnhs) 2010-2012; aged 6-17 years; had blood taken; exclusion criteria: no.

Keywords: 25 hydroxyvitamin d 6-17 years old vitamin d deficiency